Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Response Biomedical's Heart Failure Dx Test

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared a Response Biomedical point-of-care test that serves as an aid in diagnosing heart failure, the company said today.
 
The RAMP NT-proBNP test identifies the marker for BNP, which is secreted from the heart’s left ventricle in response to pressure overload, and it regulates blood pressure, electrolyte imbalance, and fluid volume.
 
Elevated levels of the NT-proBNP indicate heart failure, and can be used for early detection and management, according to Vancouver, BC-based Response Biomedical.
 
The test “supports the drive for speed and accuracy of diagnosis for patients presenting in emergency rooms and for early detection in ambulatory care,” said Response Biomedical CEO S. Wayne Kay.
 
Kay also said that the test is “clinically concordant” with Roche’s Elecsys proBNP test, allowing hospitals to standardize their decisions based on tests from their emergency rooms and central labs.
 
Affecting nearly 17 million people worldwide, heart failure is “the single most frequent cause of hospitalization in people over 65 years,” the company said.
 
Response Biomedical recently granted Roche Diagnostics the rights to market its cardiovascular point-of-care tests.  

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.